Drug Database
BE

benzoyl peroxide (Exact)

✓ Approved

Teva Pharmaceutical Industries Ltd. · Small Molecule · Small Molecule

What is benzoyl peroxide?

benzoyl peroxide is a small molecule developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesExact
CompanyTeva Pharmaceutical Industries Ltd.
Drug ClassSmall Molecule
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

Therapeutic Indications

benzoyl peroxide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersAcne✓ Approved

Related Research Articles

PubMedJournal of nanobiotechnology2026-09-19

Visualized self-propelled nanorobots overcome tumor barriers for boosted photothermal-nanocatalytic synergistic therapy against triple-negative breast cancer.

Wang Ze Z, Chu Hongyu H, Du Jincheng J, Liang Hao H et al.

Conventional nanozyme-based therapeutics for triple-negative breast cancer (TNBC) are severely hindered by insufficient tumor penetration and lysosomal degradation-induced enzyme inactivation, crippling therapeutic efficacy. Herein, we rationally construct visualized dual-propelled Janus PDAPdAu nanorobots (PPA NBs) with cascade catalytic activity for synergistic photothermal-nanocatalytic therapy of TNBC. Powered by near-infrared light-triggered thermophoresis and nanozyme-fueled oxygen propulsion, PPA NBs realize deep tumor penetration and lysosomal escape. PPA NBs exhibit catalase-mimicking activity to alleviate tumor hypoxia through hydrogen peroxide decomposition, and glucose oxidase-mimicking activity to deplete glucose and downregulate heat shock proteins, thus sensitizing TNBC to photothermal therapy (PTT). Localized hyperthermia further enhances nanozyme catalysis, forming an amplified synergy between nanocatalytic therapy and PTT that affords an outstanding 97% tumor inhibition rate. Furthermore, PPA NBs act as excellent fluorescent biosensing probes for visual lesion localization. Overall, this work provides visual diagnosis and advanced TNBC phototherapy strategies, a reliable paradigm for cancer patients' health monitoring and treatment.

PMID 42760553
Read full article →
PubMedBMC medical imaging2026-09-19

FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer.

Markus Maria M, Sartor Hanna H, Bjurberg Maria M, Minarik David D et al.

[18 F]-fluorodeoxyglucose (FDG) positron emission tomography combined with computed tomography (PET-CT) is used for staging and treatment response evaluation in patients with locally advanced cervical cancer. While the maximum standardised uptake value (SUVmax) is a commonly used PET parameter, volume-based parameters (metabolic tumour volume (MTV) and total lesion glycolysis (TLG)) may offer superior predictive value. This study aimed to investigate the predictive value of different treatment response outcomes assessed with PET-CT, using both standard and volume-based PET parameters. We retrospectively analyzed 133 patients with locally advanced cervical cancer treated with (chemo)radiotherapy who underwent PET-CT pre- and post-treatment. SUVmax, MTV and TLG were semi-automatically extracted from all scans, including tumour, lymph nodes and metastases. Treatment response was classified as complete metabolic response (CMR) (complete resolution of FDG uptake in all lesions), partial metabolic response (PMR) (> 25% reduction of SUVmax/MTV/TLG), progressive metabolic disease (PMD) (> 25% increase of SUVmax/MTV/TLG or appearance of new FDG-avid lesions) or stable disease (SD) (does not qualify for CMR, PMR or PMD). The three PET-parameters were analysed separately. PMR and SD were analysed as one group due to limited number of events. Associations between treatment response and overall survival (OS) as well as recurrence (binary variable) were analysed through Cox and logistic regression models, respectively. For recurrence (binary variable), the odds ratio (OR) was 1.2 for patients with PMR/SD for SUVmax, MTV and TLG, while in the group of patients with PMD, it was 1.7 for SUVmax and 1.8 for MTV and TLG, using CMR as reference (i.e. for CMR, the OR is 1.0). The hazard ratio (HR) for OS was 4.0 for patients with PMR/SD and 16.0 for those with PMD, based on SUVmax; for MTV and TLG, HRs were 2.9 for patients with PMR/SD and 16.0 for those with PMD, using CMR as reference (HR 1.0). C-index from adjusted Cox models were comparable: 0.84 for SUVmax, and 0.86 for both MTV and TLG. FDG-PET/CT-based assessment of treatment response is a strong predictor of recurrence and overall survival in locally advanced cervical cancer. SUVmax, MTV, and TLG demonstrated similar predictive performance.

PMID 42760525
Read full article →
PubMedFrontiers in oncology2026-09-19

Immune checkpoint inhibitors plus chemotherapy for early-stage or locally -advanced triple-negative breast cancer: a systematic review and Bayesian network meta-analysis of randomized trials.

Leng Ying Y, Dan Jiaqiang J, Heng Qiuhan Q, Li Junyan J

Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become a cornerstone in managing early and locally advanced triple-negative breast cancer (TNBC). Yet direct comparative evidence on the relative efficacy and safety of different PD-1/PD-L1 agents and treatment strategies-particularly neoadjuvant-only versus perioperative, "full-course" approaches-remains limited. To guide clinical decision-making, we performed a Bayesian network meta-analysis (NMA) comparing six specific ICI-based regimens and four overarching treatment strategies. We systematically searched PubMed, Embase, Cochrane Library, and Web of Science from database inception through February 25, 2026. Eligible randomized controlled trials (RCTs) enrolled patients with previously untreated early or locally advanced TNBC and compared ICI plus neoadjuvant chemotherapy with chemotherapy alone. The primary endpoint was pathological complete response (pCR); secondary endpoints included overall survival (OS) and grade ≥3 adverse events (AEs ≥3). We assessed risk of bias using the Cochrane RoB 2 tool. A Bayesian random-effects model was applied for the NMA; effects are reported as odds ratios (ORs) or hazard ratios (HRs) with 95% credible intervals (CrIs). Treatment rankings were derived from surface under the cumulative ranking curve (SUCRA) values. Certainty of evidence was evaluated using the GRADE framework, supplemented by the CINeMA tool. Eight RCTs involving 2,073 patients met the inclusion criteria, encompassing four strategic treatment categories and six specific ICI-containing regimens. For pCR, PD-1 (neoadjuvant) + CT (OR 2.56, 95% CrI 1.55-4.22), PD-L1 (perioperative) + CT (OR 2.00, 95% CrI 1.29-3.09), and PD-1 (perioperative) + CT (OR 1.71, 95% CrI 1.39-2.10) each significantly improved pCR rates versus chemotherapy alone, though certainty of evidence ranged from moderate to very low. PD-L1 (neoadjuvant) + CT showed a numerical trend toward higher pCR (OR 1.41, 95% CrI 0.98-2.01) without reaching statistical significance. Regarding OS, both PD-L1 (neoadjuvant) + CT (HR 0.24, 95% CrI 0.08-0.72) and PD-1 (perioperative) + CT (HR 0.63, 95% CrI 0.48-0.82) demonstrated significant survival benefits over chemotherapy. In sensitivity analyses, durvalumab (neoadjuvant) + CT and pembrolizumab (perioperative) + CT yielded identical HRs (0.24 and 0.63, respectively). Safety profiles varied: camrelizumab (perioperative) + CT (OR 0.60, 95% CrI 0.34-1.04) and pembrolizumab (neoadjuvant) + CT (OR 0.53, 95% CrI 0.28-1.01) suggested reduced risks of AEs ≥3, but these findings did not achieve statistical significance and were supported by low-to-very-low certainty evidence. ICI-chemotherapy combinations consistently improve pCR rates in early and locally advanced TNBC. Notably, while our analysis hints at potential survival advantages with neoadjuvant PD-L1 blockade and perioperative PD-1 inhibition, these signals derive from only three studies and remain hypothesis-generating rather than practice-changing. Future head-to-head RCTs are warranted to confirm these observations and to better define long-term safety profiles. https://www.crd.york.ac.uk/prospero/, identifier CRD420261385223.

PMID 42761076
Read full article →
PubMedJournal of food science2026-09-19

Enhancing Repeated Frying Stability of Soybean Oil by Blending With Beef Tallow.

Zhang Xiaoyu X, Wang Qiaojun Q, Yu Man M, Xiang Qin Q et al.

Frying can bring desirable flavor and crispness to food, with frying oil performance being crucial for product quality and safety. This study investigated the effects of blending beef tallow (BT) with soybean oil (SO) on the oxidative stability, sensory quality, and safety profile of frying oil subjected to repeated use. Five blends with saturated fatty acid (SFA) levels ranging from 18.95% to 28.82% were evaluated. Increasing the BT proportion significantly improved frying stability. Compared to pure SO, the blend with the highest SFA content (S5, 28.82% SFA) showed the greatest reduction in oxidation indices, including a 38.2% decrease in acid value and a 30.0% decrease in peroxide value. After 20 frying cycles, BT/SO blends also reduced harmful compounds such as benzo[a]pyrene (by 10.6%-34.1%) and total polar compounds (by 17.5%-27.1%). Sensory evaluation indicated that blends such as S4 (26.55% SFA) suppressed sour odor and enhanced buttery and roasted notes, while excessive BT introduced an undesirable cowy odor. Fatty acid analysis confirmed that BT blending slowed polyunsaturated fatty acid degradation and trans fatty acid formation. In conclusion, moderate BT addition, particularly at approximately 26.55% SFA, effectively improves the oxidative stability and flavor quality of repeatedly used frying oil. PRACTICAL APPLICATIONS: This study offers a practical blending strategy for the food industry to enhance the performance of repeatedly used frying oils. The incorporation of an appropriate amount of BT into vegetable oil can effectively improve oil stability. Manufacturers can extend oil service life, reduce harmful compound formation, and maintain desirable sensory attributes of fried foods. These benefits make the approach suitable for both large-scale food production and small-scale foodservice operations.

PMID 42760792
Read full article →
PubMedAAPS PharmSciTech2026-09-19

Comprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies.

Gomes Isabela Pereira IP, Rivelli Graziella Gomes GG, Bagno Flávia Fonseca FF, Hojo-Souza Natália Satchiko NS et al.

Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH, oxidative stress, temperature, and light. We have produced a squalene nanoemulsion (CTVad1) to support the clinical development of new vaccines. This study aimed to develop and validate an HPLC method for squalene quantification in SpiN-Tec, a recombinant protein vaccine against COVID-19. We also aimed to evaluate the stability of the CTVad1 adjuvant and SpiN-Tec under controlled storage conditions. A reversed-phase HPLC method was developed and validated, and comprehensive forced degradation studies were performed on the raw material and SpiN-Tec under acidic, basic, oxidative, thermal, and photolytic conditions to demonstrate the stability-indicating capability of the method. Physicochemical, morphological, and biological characteristics were assessed, and stability studies of both the vaccine and the CTVad1 adjuvant were performed under accelerated and long-term conditions. The HPLC method was selective, precise, accurate, linear, and robust. Squalene raw material degraded under all tested conditions, whereas formulation in nano-sized globules improved its stability, with degradation observed only under hydrogen peroxide and light exposure. CTVad1 remained stable over time, exhibiting only minor, non-critical changes within the specification limits in both accelerated and long-term stability studies, regardless of the glass packaging used (clear or amber). In addition, the SpiN-Tec vaccine maintained its physicochemical and biological integrity under all tested conditions, with all evaluated parameters remaining within the established specification ranges. Our findings demonstrate that proper formulation, packaging, and storage conditions can preserve squalene stability in nanoemulsion-based vaccines, ensuring the quality, safety, and efficacy of the SpiN-Tec vaccine and its adjuvant throughout shelf life.

PMID 42760453
Read full article →
PubMedFrontiers in endocrinology2026-09-19

Optimizing family building in women of advanced reproductive age: a Faster-Fewer-and-Finished approach.

Sunkara Sesh K SK, Venetis Christos C, D'Hooghe Thomas T, Duncan Francesca E FE et al.

Delayed parenthood is a defining feature of contemporary reproductive medicine, fundamentally reshaping reproductive planning and increasing reliance on medically assisted reproduction (MAR). For women of advanced reproductive age (ARA), this shift exposes a potential disconnect between conventional treatment pathways and the biological constraints of ovarian ageing and a rapidly narrowing reproductive window. This risks preventable delays, cumulative treatment burden, and suboptimal outcomes in this population. Addressing these challenges requires deliberate adaptation of current clinical strategies to minimize avoidable delays in assessment and treatment, while ensuring timely, optimized, and outcome-focused care. In this Perspectives article, which is based on expert consensus opinion, we propose a hypothesis-generating framework - the Faster-Fewer-and-Finished (3F) approach - in which expedited evaluation, tailored cycle sequencing, and a patient-tailored 'finish' criterion are applied to maximize time-to-first-live birth or to arrive at a shared decision on how or if to continue, with treatment decisions anchored by individual age and ovarian reserve. The 3F approach prioritizes achieving a live birth or ideal family size in the shortest possible time by advocating the 'fewest' number of ovarian stimulation cycles necessary. While more than one cycle may be unavoidable, the emphasis is on early strategic tailoring of treatment according to age category, efficiency of intervention, and minimizing biological and emotional attrition. By aligning treatment strategies with both the realities of ovarian ageing and the wishes and life priorities of ARA patients, the 3F approach integrates established principles of MAR into a time-critical, outcome-driven theoretical framework for infertility care.

PMID 42761074
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about benzoyl peroxide